Related Experiment Video
Updated: Feb 24, 2026

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells
Published on: August 1, 2025
A retrospective analysis comparing APCEDEN® dendritic cell immunotherapy with best supportive care in refractory
Chaitanya Kumar1, Sakshi Kohli1, Srikanth Chiliveru1
1APAC Biotech Pvt Ltd, Gurgaon, India.
Aim:
A retrospective survival benefit analysis of APCEDEN®, APAC BIOTECH Pvt Ltd 69, Jacranda Marg, DLF PHASE II, Gurugram, Haryana, India, an autologous dendritic cell-based product for management of refractory solid malignancies, was performed in comparison with a control group.
Methods:
Subjects (retrospective data) whose survival data, geographical region, age, gender, ECOG performance status and stage of disease that could be matched with the treatment group were considered for analysis.
Results:
The analysis suggests a significant survival benefit of 199 days for the APCEDEN therapy treatment group when compared with the control group (356 vs 157 days). The event-free survival time of APCEDEN therapy was 439 days in patients who demonstrated an objective response at first evaluation as per immune-related response criteria.
Conclusion:
APCEDEN demonstrated highly convincing survival benefits when compared with the control group.
Related Concept Videos
Tumor Immunotherapy
Treatment Resistant Cancers
Cancer Survival Analysis

